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   INTRODUCTION 
Vitiligo was referred by various names such as ‘Sufaid Dagh’, 
‘Phulbahari’, ‘Bars’, ‘Bahak’, ‘Kilas’, ‘Palita’, ‘Kodha’, ‘Sweta Kushta’, 
‘Dhawal Kustha’.[1] However origin of the term ‘Vitiligo’ is obscure. 
Vitiligo is a common skin disorder affecting between 1-2% of world 
population.
[1]  
In India and different countries across the globe the incidence 
ranges from 0.1 - 8.8%.The highest incidence has been reported in India 
followed by Mexico and Japan.
 [1]
 It affects 50% of patients before 20 years 
of age and 25% before 10 years of age, resulting in a significant pediatric 
problem.
 
   
It is characterised by completely depigmented milky white macules of 
varying sizes. This disorder does not cause restriction in capacity to work 
or expectancy of life. It leads to cosmetic disfigurement causing 
considerable psychological trauma to patients.
[2] 
 
Various theories such as autoimmune, autocytotoxic , aberration of cellular 
immunity with melanocyte destruction, inhibition of melanogenesis and 
aberration of vitamin D3 metabolism  are proposed as possible causes.
[3] 
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There are various medical and surgical modalities available for the 
treatment of vitiligo, but all of these cannot be used in children. Medical 
therapy is considered the first line of management in this age group.
[4]
  
60% of pediatric patients respond atleast particularly to application of 
medium strength to potent topical steroids alone.
 [4] 
 
Tacrolimus is a macrolide immunosuppressant that is approved for use in 
adult patients and pediatric patients above the age of 2 years. It acts by 
inhibiting the activation and maturation of T cells by means of blocking the 
action of calcineurin and interleukin (IL)2, IL-4and IL-5 transcription. In 
vitro studies have demonstrated the positive effects of this drug in vitiligo 
by showing an increased proliferation of melanocytes and melanoblasts in 
epidermal cell cultures. The repigmenting effect of tacrolimus has been 
reported to be site dependent and best results are seen on face and neck.
[5] 
 
Therefore the present study was done to compare the efficacy of 0.03% 
tacrolimus alone and 0.03% tacrolimus and mid potent topical steroids. In 
fact the site dependent effect of tacrolimus gives an indirect support to the 
idea of combined role of topical tacrolimus and topical steroids. 
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REVIEW OF LITERATURE 
 
Vitiligo is a common, acquired, primary, progressive, melanocytopenia of 
unknown  etiology, manifesting clinically as  circumscribed achromic 
macules often associated with leucotrichia and histologically by 
degeneration and disappearance of melanocytes in  the involved skin and 
not infrequently in pigment epithelium of the eyes, leptomeninges and 
inner ear.
[6,7] 
Historical aspects 
The earliest authentic reference of the condition can be traced back to the 
period of aushooryan (2200BC), in the classic tarikh – e - tib – e - iran. 
Pharonic medicine in ebers papyrus (1550BC) described two types of 
diseases affecting the colour of the skin, with tumours, probably leprosy 
and with only colour change, probably vitiligo.
[8] 
The origin of the term vitiligo is obscure, like the disease itself. Some 
believe that it is derived from the latin word ‘vitelius’ meaning vale i. e.,  
pale pink flesh of calf, since the clinical lesions resembled the white 
patches of spotted calf, while other believed that it originated from latin 
word ‘vitium’ meaning blemish. The roman physician celsus first used the 
term vitiligo in second century A D. It is interesting to note that the Rig-
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Veda (6000 BC or earlier) named leukoderma as kilas meaning white 
spotted deer.
 [9] 
The Indian sacred book Atharva Veda dating back to 1400 BC refers to 
disease as kilas meaning white in Sanskrit. In charaka samhitha dated back 
to 800 BC refers to disease as svitra. In the Sanskrit dictionary Amarkosha 
(600AD), the word is translated as spreading whiteness. In vinayak pitak 
(624 – 544BC) the sacred book of Buddhism there is mention of disease 
associated with white spots.
[10] 
 
The Manu smruti dating back to 200 BC mentions the word Sweta Kustha 
which means that which make the body ugly or spoils the blood.
[11] 
 
In Amarkosha the term svitra has been used synonymously with 
padosphota meaning flower of legs, twakpuspi meaning flower of skin and 
sidhmati which means spreading whiteness.
[12] 
 
Moritz Kaposi was one of the first to describe the histopathological 
features of vitiligo.
 [11]
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EPIDEMIOLOGY 
The prevalence of vitiligo in childhood (age < 12 years) has been quoted to 
be around one quarter of vitiligo patients of all ages.
[13]
 Both sexes are 
equally affected. The female prevalence is higher due to greater concern 
about the cosmetic defect.
[1] 
Vitiligo appears to be observed more commonly in sun-exposed areas and 
in darker skin types.
 [1]
 It affects people with skin types 3 and 4. Diet which 
is poor in protein and cuprominerals is thought to be contributory to 
vitiligo.
[14] 
Vitiligo may develop at any age. Onset of the disease is usually below 10 
years of age. The mean age of onset of childhood vitiligo in an Indian 
study was 6.2 years.
[14]
 Family members of the affected children have 
higher incidence of vitiligo and other autoimmune diseases.
[15]
 
 AETIOPATHOGENESIS 
The pathogenesis of vitiligo is complex and not well understood. Over the 
years multiple aspects of biochemical, immunological, genetic aspects play 
a role and so far no convincing model describing the interplay of all 
contributing factors have been formulated.
[16,17] 
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GENETIC FACTORS AND INHERITANCE 
At present the consensus is that familial incidence is between 20 -30%.
[18] 
Inheritance was thought to be autosomal dominant with variable expression 
and incomplete penetrance.
[19-21] 
The possibility of autosomal recessive or 
polygenic inheritance with its somatic expression decided by precipitating 
factors has been suggested. Monozygotic twins have been seen to have 
vitiligo with a similar or dissimilar mode of onset, type, extent and course 
of the disease.
[22]
Various susceptibility loci for vitiligo are AIS1(chr1), 
AIS2(chr 7),AIS3(chr8) and SLEV1(chr 17)
. 
Association of vitiligo with 
transporter associated with antigen processing protein- 1(TAP-1) gene is 
suggestive of possible role of MHC class I antigen in antimelanocyte 
autoimmune response.
[23]
 An association between the catalase gene (CAT) 
and vitiligo has been suggested.
[24]
 VIT- 1 gene which maps to 
chromosome 2p16 has also been associated with vitiligo. Recently variants 
of gene NALP1 on chr17p13 were found to be associated with group of 
epidemiologically associated autoimmune and autoinflammatory disease 
including generalised vitiligo and autoimmune thyroid disease.
[25] 
 No definite human leukocyte antigen (HLA) association is established for 
vitiligo although increased incidence of HLA DR4 in black people, HLA 
B13 in Morocean Jews and HLA BW35 in Yemenite Jews with vitiligo 
have been reported.
[25]
A familial incidence of diabetes mellitus and thyroid 
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disease has been noted in cases of vitiligo.
[26] 
Atopy is another familial 
association.
[18]
Various triggering factors include emotional stress, drug 
intake, infections, trauma/injury
[1] 
THEORIES ON THE PATHOGENESIS: 
Besides genetic predilection, diverse epigenetic factors also play a role in 
etiopathogenesis. An alteration in the microenvironment of epidermal 
melanin units , related possibly to immunological, neurochemical factors 
has been presumed. The following hypothesis have been proposed.
[27]
 
1. NEURAL HYPOTHESIS[16,17] 
Evidence in favour are 
1. The peripheral nerve endings may secrete a substance that is 
cytotoxic to melanocytes and causes their destruction. This is 
supported by segmental variety of vitiligo which occurs in specific 
dermatomes. 
2. Associated with encephalitis and trauma that causes peripheral nerve 
damage. 
3. Production of abnormal neuropeptides and nerve growth factors 
which are toxic to melanocytes. 
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4. Abnormal autonomic function such as increased adrenergic tone, 
increased norepinephrine and an increased concentration of 
catecholamines. 
5. The common embryologic origin of melanocytes and the nervous 
system. 
6. Demonstration of direct contact between cutaneous free nerve 
endings and epidermal melanocytes in vitiligo macules. 
7. Repigmentation in segmental lesion was observed by administration 
of nialamide, an oral MAO inhibitor to suppress metabolism of 
catecholamines at sympathetic nerve endings.
[18]
 
 
2. SELF DESTRUCTIVE THEORY BY A.B.LERNER. 
This hypothesis envisages that an intermediate metabolite of melanin 
synthesis cause destruction of melanocytes or that the normal process of 
melanosome degradation proceeds unabated to cause melanocyte death. 
Elimination of toxic melanin precursors does not possibly occur, eventually 
causing death of melanocytes. Supportive evidence includes : 
1. The appearance of vitiligo in areas which are usually darkly 
pigmented. 
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2. Phenolic compounds have the potential to produce vitiligenous 
lesions. 
3. Tyrosine, dopa and tryptophan have a selective toxicity towards 
melanocyte. 
A phenolic derivative may emerge as a degradation product of 
melanogenesis can cause tyrosinase inhibition.
[27] 
The enzyme thioredoxin reductase, a free radical scavenger is 
located on the membrane of melanocytes. This enzyme is inhibited 
by calcium. Higher extracellular calcium levels cause increased 
superoxide radicals that lead to inhibition of tyrosinase by upsetting 
the equilibrium of oxidised and reduced thioredoxin in the 
epidermis, which later causes cell death.
 [28]
 
 
 
3. AUTOIMMUNE THEORY  
An aberration of immune surveillance has been surmised as the basic event 
responsible for dysfunction and destruction of melanocytes. Primarily there 
may be some kind of biochemical trauma to melanocytes resulting in 
release of antigenic substances and subsequent autoimmunisation. 
Alternatively there may be immune cells directed against the component of 
autologous melanocytes. The frequent association of vitiligo with 
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autoimmune disorder and frequent presence of autoantibodies against 
thyroid, thyroglobulin, adrenal, parietal cells, malignant melanoma and 
halo nevus. 20-30% of patients with vitiligo can have an autoimmune 
endocrine disorder. There have been reports of IgG antibodies to 
melanocytes, nevus cells and melanoma cells. Complement fixing 
antibodies against vitiligo is seen in mucocutaneous candidiasis, alopecia 
universalis or multiple endocrinopathies. 
Cell mediated immune defects such as decreased responses to 
dinitrochlorobenzene; quantitative T cell defects, defective natural killer 
cell activity and decreased lymphoproliferative responses to multiple 
mitogens. There is significant decrease in CD45A+ and significant increase 
of HLA-DR+ cells indicating the presence of activated peripheral T cell 
dysregulation. Hence both humoral and cell mediated immune defects are 
involved. 
 
4. CONVERGENCE THEORY. 
Convergence theory states that genetic factors have a role in causation of 
vitiligo in addition to other elements such as stress, accumulation of toxic 
compounds, infection, autoimmunity, mutations, altered cellular 
environment, and impaired melanocyte migration and proliferation.
[5] 
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5. MELANOCYTE GROWTH FACTOR REDUCTION 
HYPOTHESIS.
[29]
 
According to this theory there is a growth factor produced by 
keratinocytes, fibroblasts, various other tissues which regulate the normal 
density of melanocytes and the deficiency of the growth factor leads to 
depigmentation in vitiligo. 
 
6. ANTIOXIDANT DEFICIENT THEORY. 
There is breakdown in the antioxidant defence in the epidermis leading to 
melanocyte toxicity. An abnormally high level of catecholamine discharge 
in epidermis and dermis could lead to ischemia and subsequent 
overproduction of reactive oxygen species. This oxidative stress leads to  
accumulation of high level of 6,7 biopterins which inhibits tyrosinase 
activity and extremely cytotoxic to melanocytes.
[30] 
7. A NEW INTEGRATED THEORY. 
It takes into account melanocyte detachment and transepidermal 
elimination, neural- biochemical, and autoimmune hypothesis. It proposes 
that non segmental vitiligo is  a primary melanocytorrhagic disorder and 
altered melanocyte responses to friction and possibly other types of stress, 
inducing their indolent detachment and subsequent transepidermal loss. 
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Adhesion system of melanocytes is far weaker and loss of dendricity could 
also affect the melanosome transfer and contribute to depigmentation. 
Damaged melanocytes may release melanosomal antigens which could 
induce an immune response.
[31] 
8. APOPTOSIS IN VITILIGO MELANOCYTES. 
It can be induced by variety of cytokines, some environmental chemicals or 
other molecular mechanisms. The outcome of the signal depends on the 
balance between pro- apoptotic and anti-apoptotic factors. Caspase -3 is the 
key mediator of apoptosis and accelerates a cascade of caspases leading to 
degradation of the cell.
[31] 
 
CLINICAL FEATURES 
A typical lesion is a well defined depigmented macule, which often shows 
variable number of depigmented hair and without any change in skin 
texture. Onset of the lesions is usually insidious. The disease is progressive 
in nature as a rule and course is virtually unpredictable The initial lesion 
may be macules varying widely in size, shape, number and location. 
Frequently, the initial macule occurs on the exposed  areas (such as the 
dorsal surface of hands, elbows, feets, legs, knees, neck and face), body 
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folds (such as axillae, groin, and sub mammary region in women), lips or 
genitalia.
6,32 
The initial unifocal lesion may be followed by the appearance of new 
lesions elsewhere.  
 In less than 25% of cases the onset may be multifocal.
 [6]
 Involvement of 
pretibial region, palms and sole are quite common in India.
 [18] 
Achromotrichia is a common feature of vitiligo lesions on hairy parts. 
White hair is of some diagnostic and prognostic significance, the former 
because they help in differentiation from other hypopigmented macules 
and latter because they indicate poor repigmenting capacity.
 [33] 
 
Vitiligo vulgaris is the most common clinical type in childhood vitiligo, 
followed by focal vitiligo and segmental vitiligo. Mucosal vitiligo is rarer 
in children compared to adults. The rarest type seen in childhood vitiligo is 
the universal vitiligo.
 [34] 
Common initial site of onset of both non segmental vitiligo and segmental 
vitiligo in children is the face and neck. In nonsegmental vitiligo, initial 
lesions are periocular, perinasal or perioral and gradually spread to other 
body parts. Perineum, perianal area and in infancy, the diaper area may be 
the initial site of occurrence of lesions. Majority of the children have less 
than 20% body surface involvement. 
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Scalp leukotrichia is a frequent finding in children with vitiligo and their 
family members. 
Koebner’s phenomenon can be noted in both segmental and nonsegmental 
vitiligo in children, more commonly in the latter type. Koebner’s 
phenomenon is more common in childhood vitiligo because of higher 
mobility and playfulness in this age group. Presence of Koebnerisation is 
indicative of disease activity.
 [34] 
Emotional trauma and repression have been noted to be responsible for 
very sudden onset, rapid extension and spread of lesion. Such cases are 
referred to as ‘valeceo’ type vitiligo. 
A positive family history, fewer lesions, less than 5% of body surface area 
involvement, frequent segmental involvement, and greater difficulty in 
treatment but relatively better prognosis are the hallmarks of childhood 
vitiligo.
 [35] 
Morphological variations on the typical vitiligo macule
 [36] 
1. Trichrome vitiligo refers to the presence of intermediate colour; this 
is a uniform tan coloration that is narrow to broad interface between 
the normally pigmented skin and central depigmented macule.  
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2.  Quadrichrome refers to the fourth colour; this is macular 
perifollicular or marginal hyperpigmentation seen in some cases of 
repigmenting vitiligo. 
3. Pentachrome vitiligo also may be observed. This includes a 
depigmented macule, tan, brown hyperpigmentation, blue-gray 
hyperpigmentation and normal pigmentation. 
4. Blue vitiligo corresponds to vitiligo macules occurring in sites of 
post inflammatory hyperpigmentation.  
5. Inflammatory vitiligo has an erythematous, raised border. 
6. Confetti macules, which are typical in colour but only 1 to 2 mm in 
diameter, may occur randomly or may be perifollicular. 
 
Classification 
1. Classification of vitiligo according to extent of involvement and the 
distribution of depigmentation.
[37,38]
 
a. Focal vitiligo / vitiligo areata is an isolated macule or a few 
scattered macules: the macules are limited in both size and 
number.  
b. Segmental Vitiligo: Segmental vitiligo is characterized by 
unilateral macules and patches in a dermatomal or quasi-
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dermatomal distribution. This tends to have an earlier onset, not 
associated with other autoimmune diseases. This type occurs 
commonly in children. Alteration in neural peptides is implicated 
as the pathogenesis. No koebnerisation present. More than 50% 
of the cases have patches of white hair known as poliosis. 
c.  Generalized vitiligo / Vitiligo vulgaris: This is the most common 
type of vitiligo are usually widely or symmetrically distributed. 
d. Acrofacial vitiligo involves distal fingers and periorificial facial 
areas. 
e. Lip – tip vitiligo- refers to a type where there is involvement of 
mucous membranes like lips, distal penis, nipples and distal parts 
of fingers and toes. 
f. Vitiligo universalis / Universal vitiligo- In this type almost the 
entire body surface is achromic, with only few islets of normally 
coloured or hyperpigmented skin. 
g. Combination Vitiligo: very rarely vitiligo vulgaris and segmental 
vitiligo are seen in the same patient. 
2. Classification depending on prognosis of vitiligo.[1,5] 
a. Progressive vitiligo (V1) – Vitiligo with developing new lesions, 
increasing old lesions and lesions with ill-defined borders. 
b. Quiescent vitiligo (V2) – Vitiligo with no new lesions, stationary 
old lesions, decreasing lesions. 
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3. Classification based on sweat stimulation studies.[1,5] 
a. Type A is non dermatomal. It has potential for life long 
evolution, associated with koebner’s phenomenon and frequently 
with autoimmune diseases. 
b. Type B is dermatomal.  It has rapid onset and evolution. It has a 
stable course. 
 
4. Based on presence or absence of melanocytes. 
a. Absolute 
b. Partial 
5. Based on etiopathogenesis. 
a. Immune 
b. Neural 
c. Chemical 
 
6. Indian classification. 
a. Segmental vitiligo (Vitiligo Zosteriformis). 
b. Non segmental (Focal vitiligo, acrofacial vitiligo, vitiligo 
vulgaris, mucosal vitiligo). 
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Assessing a person with vitiligo
 [39] 
Determine the person’s skin type (that is skin colour and ability to tan) 
Determine whether the person has non segmental or segmental vitiligo. 
Ask about previous episodes of spontaneous repigmentation, previous 
treatments and their effectiveness and any trauma preceding skin changes. 
Assess the impact on quality of life. 
For people with non segmental vitiligo 
Note whether the face is affected. 
Estimate the percentage of the body surface area that is affected using the 
Rule of Nine or the Lund and Browder chart. 
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The Rule of Nine 
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Lund and Browder chart 
Adult Child 
Anatomic 
Structure 
Surface 
Area 
Anatomic 
Structure 
Surface 
Area 
Anterior head 4.5% Anterior head 9% 
Posterior head 4.5% Posterior head 9% 
Anterior torso 18% Anterior torso 18% 
Posterior torso 18% Posterior torso 18% 
Anterior leg, each 9% Anterior leg, each 6.75% 
Posterior leg, each 9% Posterior leg, each 6.75% 
Anterior arm, each 4.5% Anterior arm, each 4.5% 
Posterior arm, each 4.5% Posterior arm, each 4.5% 
Genitalia/perineum 1% Genitalia/perineum 1% 
Adult, obese >80 kg Infant <10 kg 
Anatomic structure Surface area Anatomic structure Surface area 
Head and neck 2% Head and neck 20% 
Anterior torso 25% Anterior torso 16% 
Posterior torso 25% Posterior torso 16% 
Leg, each 20% Leg, each 16% 
Arm, each 5% Arm, each 8% 
Genitalia/perineum 0% Genitalia/perineum 1% 
Ask about the duration of lesions and whether they are active and 
progressing, stable or regressing. 
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Vitiligo area scoring index.
 [40] 
The percentage of vitiligo involvement is calculated in terms of hand units. 
One hand unit (which encompasses the palm plus the volar surface of all 
digits) is approximately equivalent to 1% of the total body surface area. 
The degree of pigmentation is estimated to the nearest of one of the 
following percentages: 
100% - complete depigmentation, no pigment is present.  
90% - specks of pigment present. 
75% - depigmented area exceeds the pigmented area. 
50% - pigmented and depigmented areas are equal.  
25% - pigmented area exceeds depigmented area.  
10% - only specks of depigmentation present.  
The VASI for each body region is determined by the product of the area of 
vitiligo in hand units and the extent of depigmentation within each hand 
unit measured patch. 
Total Body VASI = Σ [hand units X residual depigmentation] all body sites. 
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Classification of vitiligo associations 
A. Skin disorders. 
1. Alopecia areata in 5% of cases.
[41]
 
2. Halo naevi. 
3. Psoriasis. 
4. Lichen planus. 
5. Ichthyosis vulgaris. 
6. Atopic dermatitis
[42]
 
7. Bullous pemphigoid. 
8. Dermatitis herpetiformis.
[43]
 
9. Chronic actinic dermatitis.
[44]
 
10. Twenty nail dystrophy.
[45]
 
11. Connective tissue disorders: Morphoea, Lichen sclerosis, Lupus 
Erythematosus, DLE.
[46.47]
 
12. Malignant melanoma.
[48]
 
B. Ocular Abnormalities49 
1. Iritis. 
2. Careful examination revealed depigmentation in choroid and retina 
in up to 40% of cases. 
 
. 
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C. Auditory associations50 
Sensory neural deafness. 
D. Endocrine  associations42 
1. Thyroid abnormalities: either hypothyroidism or hyperthyroidism. 
2. Diabetes mellitus: occurs in 1 to 7% of vitiligo patients and 
conversely, vitiligo occurs in 4.8% of diabetic patients. 
3. Addison’s disease in 2% of cases. 
4. APECED: Increase in incidence (13%) of vitiligo in patients with 
autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy 
has been established. This is particularly seen in patients with 
extensive vitiligo. 
5. Pernicious anaemia. 
6. Hypoparathyroidism. 
7. Myasthenia gravis and Thymoma. 
E. Hematological associations[50] 
1. Autoimmune hemolytic anaemia. 
2. Lymphomas and Leukemias. 
3. Pernicious anemia. 
F. Infections.[51] 
1. Chronic hepatitis C 
2. HIV Infection. 
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G. Syndrome associated[52,53] 
1. Vogt Koyanagi Harada syndrome – It is a bilateral, diffuse 
granulomatous uveitis. It is associated with poliosis, vitiligo, 
alopecia, central nervous system and deafness. 
2. Alezzandrini syndrome- This is an extremely rare syndrome 
characterised by unilateral impairment of vision, unilateral facial 
vitiligo and poliosis. 
 
DIAGNOSIS
 [3] 
1. Mostly clinical. Invasive and sophisticated investigations are not 
required. 
2. Woods lamp examination – In children with fair skin as it is difficult to 
differentiate a lesion of vitiligo from surrounding normal skin. It can be 
clearly visible as amelanotic macules. 
3. Complete blood count and fasting blood sugar as a routine workup in all 
patients.
 
4. Skin biopsy – in case of diagnostic difficulty. 
5. Thyroid function tests. 
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6. Screening for auto antibodies – to rule out the associated autoimmune 
disorders (Antinuclear antibodies, Anti thyroglobulin antibody, Anti 
thyroid peroxidise antibodies). 
 
HISTOPATHOLOGY: 
The most prominent feature in vitiligo is alteration of melanocytes at 
dermoepidermal junction. With silver stains or the dopa reaction, well 
established lesions of vitiligo is totally devoid of melanocytes. The 
peripheries of the expanding lesions which are hypopigmented still show 
few DOPA positive melanocytes and some melanin granules at the basal 
layer. In outer border of patches of vitiligo melanocytes are often 
prominent and show long dendritic processes filled with melanin granules.
 
Histopathology of vitiligo in sections stained with H & E. 
[55] 
It varies according to the type of the lesion that is biopsied as well as the 
biopsy site. 
1. Early evolving lesion: Focal interface changes with vacuolization of 
basal cells with few lymphocytes in the basal cell layer in close 
proximity to melanocytes are seen in early lesions. Melanin is 
slightly reduced in the basal layer but with an almost normal 
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complement of melanocytes. These are inflammatory lesions, 
histologically showing sparse to moderate dense lympho-histiocytic 
infiltrate that is the adnexal structures and even around dermal nerve 
twigs.  
2. Fully developed vitiligo of short duration: The epidermis is almost 
devoid of melanin but otherwise normal in thickness and structure. 
Melanocytes are usually absent. Such lesions often show the 
presence of several clear cells in the upper dermis, which have been 
shown to be langerhans cells. Sparse, superficial, perivascular 
inflammatory infiltrate with few melanophages. 
3. Long standing lesions of vitiligo: There is complete absence of 
melanin from the epidermis and total absence of melanocytes. 
Various structural changes are present which point towards long 
duration. Epidermis is flattened with loss of normal rete ridge pattern 
and often shows hyperkeratosis. The papillary dermis shows 
moderate thickening with increased number of fibrocytes with thin 
elongated nuclei and thickened collagen. 
4. Pigmented margins of vitiligo lesion: There is increased melanin in 
the basal layer, increased number of melanocytes often with large 
dendrites, and large melanocytes that contain abundant melanin in 
their cytoplasm. 
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5. Repigmenting vitiligo:  Epidermis is flat and thin with absence of 
melanin and melanocytes. At places it shows normalization of its 
architecture with reappearance of the rete ridge pattern, presence of 
melanin in the basal cells with few melanocytes that show heavily 
melanized dendritic process. 
Differential Diagnosis of childhood vitiligo.
 [56] 
A. Congenital 
1. Nevus Depigmentosus. 
2. Nevus Anemicus. 
3. Ash leaf spots(tuberous sclerosis) 
4. Piebaldism. 
5. Waardenburg syndrome. 
6. Hypomelanosis of Ito. 
7. Fourth stage of Incontinentia Pigmenti. 
8. Oculocutaneous Albinism. 
9. Vogt Koyanagi Harada syndrome. 
10. Alezzandrini syndrome. 
B. Acquired 
1. Inflammatory – Pityriasis alba, Lichen Striatus, Post 
inflammatory hypopigmentation. 
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2. Infection – Pityriasis versicolor, Leprosy, Post Kala azar dermal 
leishmaniasis, Pinta. 
3. Miscellaneous – Polymorphous Light eruption, Contact 
depigmentation, Lichen sclerosus et Atrophicus, topical steroid 
abuse. 
COURSE OF CHILDHOOD VITILIGO 
The course of childhood vitiligo is mostly stable or regressive; only few 
patients experience progressive or recurrent disease. Complete spontaneous 
repigmentation of non segmental vitiligo is unusual. However as compared 
to adults, the rate of spontaneous repigmentation is more in children, 
especially in tropical countries and in summer months. Repigmentation 
may be diffuse, marginal, perifollicular. Following onset segmental vitiligo 
spreads fast only along the affected dermatome. Thereafter it remains 
stationary for the rest of life.
 [34] 
PROGNOSIS.
 [57] 
There is no reliable indicator of good prognosis, but the following factors 
usually indicate a poor prognosis: 
1. Lesions on the so called resistant sites, such as bony prominences, 
nonfleshy areas, non-hairy areas and mucosal areas. They comprise 
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the sides of ankles, front of wrists, back of elbows, dorsum of feet 
and hands, palms, soles, nipples and areola. 
2. The greater the percentage of white hair the worse the prognosis. 
3. Extensive long standing disease. 
4. Associated ailments, especially systemic diseases. 
5. Heridofamilial background. 
6. Elderly age group. 
7. Iatrogenic factors (injudicious administration of topical and systemic 
medications). 
Treatment modalities of childhood vitiligo. 
1. Medical. 
a. Topical 
i. Corticosteroids. 
ii. Tacrolimus/Pimecrolimus. 
iii. Calcipotriol. 
iv. Pseudocatalase. 
v. Combination. 
b. Systemic 
i. Corticosteroids (OMP with betamethasone/ 
methylprednisolone) 
2. Phototherapy 
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i) Topical PUVA. 
ii) NB-UVB. 
iii) Systemic PUVA (>12 years). 
iv) Phenylalanine + PUVA. 
v) Excimer laser. 
 
3. Surgical therapy 
i) Conventional – mini punch graft, Suction blister epidermal graft, 
Thin Thiersch graft. 
ii) Newer cellular transplantation techniques – Epidermal cell 
suspension, Cultured melanocyte suspension, Cultured epidermis. 
4. Cosmetic camouflage. 
5. Total depigmentation using Monobenzyl Ether of Hydroquinone 
[MBEH]. 
General Aspects.
 [59] 
1. Patient should be explained the nature of the disease and its 
unpredictable course and prognosis. 
2. Reassurance. 
3. Balanced nutritious diet enriched with proteins, vitamin B complex, 
Vitamin E, and minerals such as copper, iron and zinc should be 
supplemented. 
31 
 
4. Avoidance of physical, chemical and emotional trauma as far as 
possible. 
5. Avoidance of soaps, detergents and substances containing phenolic 
compounds, rubber goods and contact exposure to other chemical 
agents. 
6. Avoidance of sunlight exposure, if necessary sunscreens are 
prescribed. 
 
A.  MEDICAL THERAPY  
a. Topical 
1. Topical steroids 
Mid potent steroids are first line therapies for children with localised 
vitiligo. Although high potency steroids are more effective in 
vitiligo, these are not recommended for use in children. Available 
studies report a 45- 60% response rate to topical steroid in childhood 
vitiligo. According to Halder et al and Cho et al the response rate in 
children was 45% and 56% respectively with topical steroids 
alone.
[61]
 It requires long term therapy for several months, increasing 
the chances of developing tachyphylaxis and local side effects like 
atrophy, telangectasia, hypertrichosis and striae. There are risks of 
serious side effects like glaucoma (prolonged application on 
periorbital vitiligo), suppression of hypothalamopituitary adrenal 
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axis and growth retardation with long term use over large body 
surface area. In order to avoid the side effects, interrupted therapy 
has to be given (application twice or once daily for 2 months 
followed by treatment free period for 2 weeks if the treatment period 
is longer than 8 months). Hence patients should be cautioned against 
inadvertent use of topical steroids.
 [34] 
 
2. Topical Tacrolimus and Topical Pimecrolimus. 
Topical calcineurin inhibitors (TCI), tacrolimus and pimecrolimus 
are effective alternatives to topical corticosteroids in terms of 
avoidance of side effects of the latter .TCIs are slower to exert 
beneficial effect compared to topical corticosteroid. Best response is 
observed on thinnest areas of the skin (eyelids).They are not 
approved for treatment of vitiligo in children below 2 years. Side 
effects are mild, transient and hence easily tolerated by children. 
However these agents are costly and may not be affordable by the 
families from low socioeconomic strata.
 [34] 
3. Topical calcipotriol 
It is a vitamin D analogue that could act in vitiligo by playing role in 
calcium regulation by 1, 25 dihydroxy vitamin D3 receptors on 
melanocytes and by regulation of calcium homeostasis. It has been 
reported to be an effective adjunctive treatment in vitiligo, enhancing 
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the efficacy of PUVA therapy.
[57] 
 Side effects are mild, transient and 
hence easily tolerated by children. However these agents are costly 
and may not be affordable by the families from low socioeconomic 
strata.
 [34] 
4. Pseudocatalase. 
Topical application of pseudocatalase and calcium chloride with 
short term suberythemogenic UVB used twice a day has been 
claimed to produce repigmentation in 90% of vitiligo patients.
 [58]
 
5. Basic Fibroblast growth Factor. 
It is capable of multiplying melanocytes from surrounding hair 
follicles surrounding the affected skin and also acts a chemotactic 
agent to direct the new melanocytes to the vitiligo patch.
 [59] 
6. Placental Extract Preparations. 
The use of human placental extract both aqueous and alcoholic has 
been widely propagated. It probably rectifies the block in the 
conversion of tyrosine to dopa and dopa to dopachrome. The best 
results have been observed in focal and acral types of lesions but 
also effective in segmental and vulgaris types. The extract is to be 
applied locally three times a day. It should be rubbed in for 3 to 5 
minutes followed by exposure to sunlight, infrared light and UV 
lamp for 15 minutes.
 [60] 
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b.  Systemic 
Corticosteroids 
Rapidly progressive generalised vitiligo in older children and 
adolescents may be treated with a short course of systemic steroid. A 
better way to avert the side effects is administering oral 
betamethasone as a single morning dose (0.1 mg/kg body weight) on 
two consecutive days in a week (oral mini pulse therapy) for 12 
weeks and thereafter reducing the dosage by 1mg/month for the next 
3 months.
 [61] 
 
c. Nutritional agents. 
Multivitamin therapy, antioxidants, minerals given for a prolonged 
period has been useful in vitiligo patients. Oral Zinc is also said to be 
effective in vitiligo.
 [57]
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B. PHOTOTHERAPY 
The mechanism of action of psoralens and UVA therapy is by increase 
of the following:- 
a. Number of functional melanocytes. 
b. Number and size of melanosomes. 
c. Number of dendrites of melanocytes. 
d. Transfer of melanosomes to keratinocytes. 
e. Tyrosinase activity. 
f. Amount of free melanin. 
g. Thickness, density and adherence of the stratum 
corneum. 
1. Topical PUVA. 
It can be used safely in younger children with limited body surface 
area [BSA] involvement. As a rule if the vitiligo macule is less than 
6 sq cm in size, usually 0.1% can be applied weekly followed 2-3 
hours later by solar UVA irradiation for 30-60 seconds. The time of 
exposure can be increased by 30 seconds per sitting and the 
frequency to twice weekly to thrice weekly sittings until the patch 
become slightly erythematous. 
Alternatively, after 2-3 h of application, the area is exposed to black 
light at a distance of 4 cm for 4-5 min. After treatment the area 
should be washed and sunscreen should be applied. The treated area 
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should not be exposed to sunlight for atleast 12 hours to avoid 
phototoxicity.
 [57] 
2. NB- UVB 
Narrow band fluorescent bulbs of Philips TL-01, each of 100W with 
an emission spectrum of 311nm are used. No side effects of oral 
psoralen, can be used in pregnancy and childhood, no post exposure 
eye protection is required and exposure time is shorter are the 
advantages of this modality. The face and neck showed the best 
results, whereas the trunk and proximal extremities had moderate 
pigmentation. Acral areas and areas of bony prominences and lower 
hair growth density are hardly pigmented. If no response is seen after 
6 months then further therapy should be discontinued.
 [62] 
3. Systemic PUVA 
The use of topical or oral psoralens and ultraviolet A radiation 
(UVA) termed PUVA. It is contraindicated in children less than 12 
years of age.
[63] 
These phototoxic compounds that enter cells and 
then absorb photons to   produce photochemical reactions that alter 
the function cellular constituents. It is used when more than 20-25% 
of the BSA is involved or in patients where other modalities fail to 
give optimum results.
[63]
 Three psoralens are used :-
Methoxypsoralen or 8-MOP, Bergaptan or 5-MOP and Trioxsalen or 
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4,5,8 trimethyl psoralen.
[64]
 Psoralens (8-MOP or TMP) are given in 
the dose of 0.6mg/kg/day ingested with food 2 hours before sun 
exposure, preferably between 11am and 1 pm..
[65]
 
The first therapeutic dose is determined by calculating the minimal 
phototoxicity dose (MPD) which is determined by phototesting. If 
phototesting is not feasible then treatment is usually started at an 
initial dose of 1-2J/cm2; 2 – 3 sittings per week. The dose is then 
increased by 0.5 J/ cm2.
 [66]
 Side effects of this therapy include 
nausea, pruritus, epigastric discomfort, nervousness, erythema, 
blistering reaction, cataract and photocarcinogenesis. If there is no 
response after 6 months or 50 treatments, PUVA should be 
terminated.
 [66]
 
4. Phenylalanine with UVA exposure 
It has been used orally and topically with UVA exposure. A 5% 
aqueous L- phenylalanine solution was orally administered 1 h 
before UVA irradiation. Using a cream containing 10 % L- 
phenylalanine over achromic areas 20 min before exposure gives 
better results.  Irradiation was twice a week as per the above 
schedule for six months. The most common areas of repigmentation 
are the arms, legs, knees and eyelids and there are no side effects. [
67] 
 
38 
 
5. Khellin with UVA exposure 
Khellin, a furanochrome isolated from the seeds of Ammi visnaga, a 
plant of the eastern Mediterranean area, has been effective a 
photosensitizer as psoralen. It is free from toxic side effects and well 
tolerated.
 [68] 
6. Excimer laser (308nm) 
The 308nm xenon chloride excimer laser is an effective and safe 
modality for the treatment of chronic stable vitiligo, with good 
results achieved in short duration of time. Treatment given twice or 
thrice weekly for 10 to 15 sittings. Initial pigmentation is observed 
by 4 to 8 weeks. It acts through immunomodulation by affecting the 
T cells. Repigmentation occurs fastest with thrice weekly treatment. 
However treatment period more than 12 weeks is required.
 [69] 
 
C. SURGICAL THERAPY 
1. Only stable localized vitiligo lesions (segmental or non segmental 
vitiligo), unresponsive to other treatment modalities are chosen for surgical 
treatment.  
2. Surgical procedures are not performed in very young children as 
segmental or stable focal lesions increase in size with body growth.  
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3. Moreover success of many procedures depends on postoperative 
immobility of the operated part, which is difficult to maintain in young 
children.  
4. Older children and adolescents may be counselled about the procedure 
and possible outcome of the surgery to achieve their cooperation. The 
restrictive factors for surgery are inability to treat larger site and risk of 
koebnerisation of the donor site. 
5. Among the various surgical techniques, suction blister epidermal 
grafting has been found to be the most convenient and effective for 
children, however prolonged immobility is required. 
6. Non- cultured autologous epidermal transplantation has been used 
successfully in children and adolescents with stable vitiligo. 
7. Cultured melanocyte transplantation is a relatively tedious technique 
requiring specialised set up, trained staff and a preparation time of 6 to 8 
weeks. Cost may be a restrictive factor for poor families in availing this 
treatment modality.
 [34] 
D. DEPIGMENTING THERAPY FOR EXTENSIVE VITILIGO. 
Recalcitrant cases of widespread vitiligo or universal vitiligo with only 
few islands of normal skin may be considered for total depigmentation 
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therapy with 20% monobenzyl ether of hydroquinone with an advice of 
lifelong stringent protection.
 [34]
 
E. COSMETIC CAMOUFLAGE. 
Good quality cover-up cosmetics (available in commercial names: 
Dermablend, Covermark, Dermacolor) may be used to cover localised 
vitiligo lesions over exposed body parts in children.
 [34]
 
 
Treatment of vitiligo at any age remains a challenge, more so during 
childhood.  
None of the available therapies is absolutely effective, and the disease runs 
a relapsing course. The art of treatment of childhood vitiligo is a fine 
balance between addressing all these issues and achieving the best result 
out of the available modalities.
 [34] 
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TACROLIMUS 
It is a macrolide immunosuppressant that comes from the fungus 
Streptomyces tsukubaensis, is a novel treatment for vitiligo.
 [5] 
MECHANISM OF ACTION 
 It binds to an immunophillin, FK binding protein (FKBP-12), 
located in the cytoplasm of T- lymphocytes. The complex formed 
inhibits the phosphatise calcineurin. This inhibition prevents signal 
transduction which ultimately halts the transcription of cytokines  
IL-2, IL-3, IL-4, IL -5, IL-8, GM-CSF, TNF-alpha and IF-gamma. 
 It also causes inhibition of histamine release from skin mast cells. 
 It causes impairment of synthesis of prostaglandin- D2. 
 Down regulation of FCeR1 on langerhan's cells. 
 Inhibition of CD4 and CD8 lymphocyte migration. 
At molecular level proliferation of both melanocytes and melanoblasts is 
significantly enhanced by tacrolimus. The concentration of stem cell factor 
in keratinocyte supernatant increases in a dose dependent manner.
 [5] 
PHARMACOKINETICS 
Systemic absorption with topical tacrolimus is minimal. After single or 
multiple doses of 0.1% tacrolimus ointment peak blood concentrations 
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were in the range of 5-20 ng/ml. The absolute bioavailability of topical 
tacrolimus is unknown. The damaged skin has higher rate of percutaneous 
absorption.
 [5] 
CONTRAINDICATION 
In patients with history of hypersensitivity to tacrolimus. 
ADVERSE EFFECTS 
Burning sensation, stinging, soreness, pruritus. 
DRUG INTERACTIONS.
 [5] 
Based on minimum extent of absorption interaction of tacrolimus with 
systemically absorbed drugs are unlikely.
 
DOSAGE AND ADMINISTRATION.
 [5] 
Tacrolimus ointment 0.03% for pediatric use and 0.1% for adults. 
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AIM OF THE STUDY 
 The aim of the study is to compare the efficacy of 0.03% tacrolimus 
alone with 0.03% tacrolimus and mid-potent topical corticosteroids 
in the treatment of childhood vitiligo. 
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MATERIAL AND METHODS 
Study design 
0.03% tacrolimus alone 
Versus 
0.03% tacrolimus and topical mid-potent corticosteroids (mometasone 
furoate 0.1%) 
This was a 2 year, randomized, open, prospective, parallel group, 
comparative study conducted in vitiligo patients attending the Vitiligo 
Clinic, Department of Dermatology, Government Chengalpattu medical 
college, Chengalpattu. 
 This study was conducted from November 2010 to October 2012. 
(2years). 
50 patients in the age group 2 to 14 years were enrolled in the study. 
During the initial visit the patients’ demographic details including the 
name, age, sex, and residential address were noted. 
A detailed history regarding the onset, duration and course of the disease, 
presence or absence of precipitating factors, family history, associated skin 
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and systemic problems, treatment taken so far and its outcome were 
recorded. 
Dermatological assessment of the disease was carried out noting down the 
sites of involvement, total body surface area involved, total number of 
patches, size and distribution of the patches, presence of white hair in the 
patch. 
Details regarding the margin of the patch, skin texture, presence or absence 
of perifollicular pigmentation, Koebner’s phenomenon, associated other 
skin and systemic problems were noted. Focal sepsis was ruled out by 
referring the patient to ENT and Dental OPD for check up. 
After collecting the preliminary reports the patient was assessed for 
eligibility for randomization. Randomization was performed according to 
computer generated random code. Treatment was identified by a code 
number either A or B according to treatment group. 
Patients with code A received treatment with 0.03% tacrolimus alone and 
patients with code B received treatment with 0.03% tacrolimus and topical 
steroids. 
The patients were asked to stick only to the study treatment as per the 
randomization code. 
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GROUP A  GROUP B 
1 3 
2 5 
4 7 
6 8 
9 10 
12 11 
14 13 
15 16 
18 17 
19 20 
22 21 
24 23 
25 26 
28 27 
30 29 
31 32 
33 35 
34 37 
36 38 
41 39 
42 40 
43 44 
47 45 
48 46 
49 50 
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Inclusion criteria 
1. Age more than 2 years and less than 14 years. 
2. Children free of chronic illness and systemic diseases. 
3. All types of vitiligo except vitiligo vulgaris irrespective of site and 
activity of the disease. 
Exclusion criteria 
1. Age less than 2 years and more than 14 years. 
2. Chronic illness like tuberculosis and lymphoproliferative diseases. 
3. Those children previously treated or at present treated with alternate 
system of medicine. 
4. Vitiligo involving more than 20% BSA. 
ADMINISTRATION OF STUDY TREATMENT 
 Patients with code A were advised to use 0.03% tacrolimus ointment 
twice daily morning and night. 
 Patients with code B were advised to use 0.03% tacrolimus morning and 
topical steroid mometasone furoate 0.1% at night for 2 months 
continuously with a gap of 1 week from subsequent application to 
reduce the side effects associated with topical steroids. However 0.03% 
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tacrolimus was applied in the morning continuously unlike topical 
steroids. 
 As with any topical application patients and caregivers were advised to 
wash hands after application. 
 Patients should minimize exposure to natural or artificial sunlight. 
 Patients should report any signs of adverse reactions to the physician. 
 Before application of the ointment the skin must be completely dry. 
 Total duration of study was 2 years. During the study period of 2 years 
patients were followed up every 2 weeks and improvement was 
assessed at the end of 1 year with the help of photographs. 
 Any adverse effects during the study were recorded with importance to 
erythema and systemic side effects. If any adverse effects were 
observed then its severity, onset, course, action taken and relationship to 
study drug were recorded. 
EFFICACY PARAMETERS 
The primary efficacy variable was the percentage change in 
depigmentation from baseline to the end of study period. 
The secondary efficacy parameters include the Physician’s Global 
Improvement assessment and Patient Global Inprovement assessment 
which was computed at the end of the study. 
50 
 
During the initial assessment, estimation of body surface area (BSA) 
involvement was assessed using Vitiligo Area Scoring Index (VASI). The 
body was divided into the following mutually exclusive regions:  
1) Face and Neck, upper limbs (excluding hands), lower limbs (excluding 
feet). 
2) Hands and feet. 
3) Genitalia and  
4) Trunk.  
Buttocks were included with the lower extremities. 
One hand unit, which encompasses the palm plus the volar surface of all 
the digits is approximately 1% of total body surface area and was used as a 
guide to estimate the baseline percentage of vitiligo involvement of any 
body region. To eliminate variation in hand size, we defined a hand unit to 
be the volar hand, including the fingers of single investigator. 
All the patients were followed up once in every two weeks, to look for any 
macular repigmentation, presence of new lesions and presence of adverse 
effects. At each follow up assessment the extent of residual depigmentation 
within each affected patch which had been present at baseline was 
estimated to the nearest of one of the following percentages: 0, 10%, 25%, 
50%, 75%, 90%, or 100%. Any new depigmented patches that developed 
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during the study were also estimated using the hand unit method and were 
included in the VASI calculation. For each body region the VASI was 
determined by the product of the area of vitiligo in hand units (which were 
set at 1% per unit) and the extent of depigmentation within each hand unit 
measured patch. 
Standardized assessment for estimating the degree of pigmentation to 
derive the Vitiligo Area Scoring Index (VASI). 
 At 100% depigmentation, No pigment is present. 
 At 90%, specks of pigment are present. 
 At 75%, the depigmented area exceeds the pigmented area. 
 At 50%, the depigmented area and the pigmented area are equal. 
 At 25%, the pigmented areas exceed the depigmented area. 
 At 10%, only specks of depigmentation are present. 
Total body VASI was then calculated using the following formula:- 
Total Body VASI = Σ [hand units X residual depigmentation] All bodysites 
Clinical photographs were taken at baseline and at each monthly follow up 
visits as an aid to the Global clinical scoring. VASI was determined by 
direct clinical examination. 
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The Physician’s Global improvement assessment evaluated the overall 
change from baseline in VASI score on a 5 point scale. 
Score Improvement in % Comments 
1. 76% - 100%.  Excellent improvement. 
2. 51% - 75%. Marked improvement. 
3. 26% - 50%. Definite improvement. 
4. 1% - 25%. Minimal improvement. 
5. 0%. No change 
Patient’s Global assessment was evaluated based on the response to the 
treatment as perceived by the patient with or without comparison to 
previous treatment if any. This was assessed in a 4 point scale. 
1. Much better. 
2. Slightly better. 
3. Same. 
4. Worse. 
Primary efficacy parameter, VASI was assessed at baseline and then 
 in two months during follow up for 12 months and Secondary efficacy  
parameters Physician’s Global assessment and Patient’s Global assessment  
were evaluated only at the end of 12 months. 
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STATISTICAL ANALYSIS 
 
The statistical analysis was carried out using statistical software STATA 
6.0. 
The Categorical variables were expressed as Frequency and percentage. 
The Quantity variables were expressed as mean and standard deviation. 
Descriptive statistics were used to evaluate baseline characteristics and 
adverse effects. 
The group comparison  for the categorical variables were analysed using 
Chi square test and for quantity variables were analysed using unpaired 
students ‘t’ test. 
The change from baseline of efficacy parameters within each treatment 
group was evaluated using the student t-test. The p value of less than 0.05 
was considered as statistically significant. 
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OBSERVATION 
 
A total of 50 patients were enrolled in the study, with 25 patients 
randomized to receive treatment with 0.03% tacrolimus only and 25 
patients to receive treatment with 0.03% tacrolimus and topical steroids. 
All 50 patients were included in the safety population. 
Type 
Tacrolimus Tacrolimus with Steroids 
Total 
Female Male Female Male 
Completed 12 12 11 12 47 
Drop Out 0 1 1 1 3 
Total 12 13 12 13 50 
Out of these 50 patients, 47 patients completed the study for the period of 
1year. Three of these patients, 1 in the tacrolimus group and 2 in the 
tacrolimus with topical steroids group, discontinued the study and their 
efficacy data was not included in the analysis. Most of the drop outs are 
between 8 to 12 weeks after commencing the treatment.  
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Age Distribution 
Age Tacrolimus Tacrolimus with Steroids Total 
2-5 yrs 2 1 3 
6-10 yrs 13 19 32 
11-14 yrs 9 3 12 
Total 24 23 47 
 
Out of the 25 patients enrolled for tacrolimus only(group A) treatment, 13 
were in the age group of 6 to 10yrs. Out of the 25 patients enrolled for 
tacrolimus and topical corticosteroids(group B) 19 were  in the age group 
of 6 to 10yrs.  
Variable Tacrolimus Tacrolimus with Steroids 
Age* 9.25 +  2.63 8.96 + 1.94 
 
*Values are expressed as Mean + S.D 
There is no significance difference between the Age distribution among the 
Tacrolimus and Tacrolimus with Steroids, p value >0.05.  
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Sex Distribution 
Sex Tacrolimus Tacrolimus with Steroids Total 
Female 12 11 23 
Male 12 12 24 
Total 24 23 47 
 
 
Out of the 25 patients enrolled for group A treatment, 12 were Males and 
other 12 were Females. Out of the 25 patients enrolled for group B 
treatment, 12 were Males and 11 were Females.  
Since P= .882 (>0.05).There is no statistical significant difference between 
the sex distribution among the Tacrolimus and Tacrolimus with Steroids 
 
8 
9 
10 
11 
12 
 Tacrolimus  Tacrolimus with 
Steroids 
Gender Distribution  
Female Male 
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Duration of disease 
Duration of Disease Tacrolimus Tacrolimus with Steroids 
Total 2.4166 yrs (n=24) 2.4391yrs (n=23) 
Female 2.4166 yrs (n=12) 2.0909 yrs (n=11) 
Male 2.4166 yrs (n=12) 2.7583 yrs (n=12) 
 
 
The mean duration of vitiligo was 2.416 yrs in patients enrolled for 
Group A and 2.491 yrs in the group B. 
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Type of Vitiligo 
Type 
Tacrolimus Tacrolimus with Steroids 
Total 
Female Male Female Male 
Acral 0 4 1 5 10 
Focal 12 7 9 7 35 
Segmental 0 1 1 0 2 
Total 12 12 11 12 47 
 
18 patients with focal vitiligo, 1 with segmental vitiligo, and 4 with acral 
vitiligo were included in tacrolimus only treated group. 8 with focal vitiligo 
and 14 with acral vitiligo were included in the tacrolimus and topical 
corticosteroids group. 
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Total Body VASI Reduction 
Total Body VASI 
Reduction 
Tacrolimus 
Tacrolimus with 
Steroids 
VASI 0 0.1988 (100%) 0.6154 (100%) 
VASI 2 0.1931 (97.14%) 0.6091 (98.98%) 
VASI 4 0.1775 (89.28%) 0.5113 (83.08%) 
VASI 6 0.1644 (82.68%) 0.4433 (72.04%) 
VASI 8 0.1508 (75.87%) 0.4194 (68.15%) 
VASI 12 0.1363 (68.53%) 0.4151 (67.45%) 
 
The mean total body VASI in Tacrolimus group at baseline was 0.1988 
(Taken as 100%) and in Tacrolimus with steroid group it was 0.6154 
(100%) with a p value <0.05 which is statistically significant. 
The mean total body VASI in Tacrolimus group at the end of 2 month was 
0.1931 (97.14%) and in Tacrolimus with steroid group it was 
0.6091(98.98%) with a p value <0.05 which is statistically significant. It 
shows that the onset of action was earlier in tacrolimus and topical 
corticosteroids group. 
The mean total body VASI after 12 months of therapy with Tacrolimus 
alone was 0.1363 (68.53%) and in Tacrolimus with steroid group it was 
0.4151 (67.45%) with a p value <0.05 which is statistically significant. 
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Area wise VASI reduction in Tacrolimus 
 
Area Wise 
VASI 
Reduction 
Face 
Hands
& Feet 
Lower 
Limb 
Upper 
Limb 
Genitalia Trunk 
VASI 0m 
0.1000 
(100%) 
0.1900 
(100%) 
0.3750 
(100%) 
0.0600 
(100%) 
0.2375 
(100%) 
0.2357 
(100%) 
VASI 2m 
0.0830 
(83%) 
0.1900 
(100%) 
0.3750 
(100%) 
0.0600 
(100%) 
0.2375 
(100%) 
0.2286 
(96.97%) 
VASI 4m 
0.0580 
(58%) 
0.1900 
(100%) 
0.3750 
(100%) 
0.0600 
(100%) 
0.1958 
(82.46%) 
0.2286 
(96.97%) 
VASI 6m 
0.0430 
(43%) 
0.1900 
(100%) 
0.3750 
(100%) 
0.0600 
(100%) 
0.1667 
(70.18%) 
0.2193 
(93.03%) 
VASI 8m 
0.0380 
(38%) 
0.1900 
(100%) 
0.3750 
(100%) 
0.0600 
(100%) 
0.1417 
(59.65%) 
0.1979 
(83.94%) 
VASI 12m 
0.0080 
(8%) 
0.1900 
(100%) 
0.3750 
(100%) 
0.0600 
(100%) 
0.1083 
(45.61%) 
0.1979 
(83.94%) 
 
The area wise VASI reduction in tacrolimus is as follows:- 
Face – 92 %, genitalia - 54.39 %, trunk - 16.06 %, upper limbs, lower 
limbs, hands and feet – 0 %. 
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Area wise VASI reduction in Tacrolimus and topical steroids. 
 
Area Wise 
VASI 
Reduction 
Face 
Hand 
& Feet 
Lower 
Limb 
Upper 
Limb 
Genitalia Trunk 
VASI 0m 
0.4250 
(100%) 
0.3342 
(100%) 
0.3688 
(100%) 
0.8375 
(100%) 
0.1000 
(100%) 
1.1465 
(100%) 
VASI 2m 
0.4167 
(98.04%) 
0.3342 
(100%) 
0.3688 
(100%) 
0.8100 
(96.72%) 
0.0950 
(95%) 
1.1465 
(100%) 
VASI 4m 
0.3333 
(78.43%) 
0.3342 
(100%) 
0.3063 
(83.05%) 
0.5850 
(69.85%) 
0.0950 
(95%) 
1.1250 
(85.47%) 
VASI 6m 
0.2307 
(54.27%) 
0.3342 
(100%) 
0.2125 
(57.63%) 
0.5188 
(61.94%) 
0.0375 
(37.50%) 
1.1250 
(76.92%) 
VASI 8m 
0.1473 
(34.67%) 
0.3342 
(100%) 
0.2125 
(57.63%) 
0.5125 
(61.19%) 
0.0250 
(25%) 
1.0625 
(72.65%) 
VASI 12m 
0.1473 
(34.67%) 
0.3342 
(100%) 
0.1875 
(50.85%) 
0.5125 
(61.19%) 
0.0250 
(25%) 
1.0625 
(72.65%) 
 
The area wise VASI reduction in tacrolimus and topical steroids treated 
group is as follows: - Genitalia - 75% face - 65.33%, lower limbs-49.15%, 
upper limbs - 38.89 %, trunk - 27.35%, hands and feet - 0%. 
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VASI Reduction in Vitiligo Type in Tacrolimus 
VASI 
reduction 
(at months) 
Acral Focal Segmental 
VASI 0m 0.24875(100%) 0.17895 (100%) 0.375 (100%) 
VASI 2m 0.24875(100%) 0.17184(96.03%) 0.375 (100%) 
VASI 4m 0.24875(100%) 0.15211(85%) 0.375 (100%) 
VASI 6m 0.24875(100%) 0.13553(75.73%) 0.375 (100%) 
VASI 8m 0.24875(100%) 0.11842(66.17%) 0.375 (100%) 
VASI 12m 0.24875(100%) 0.1(55.88%) 0.375 (100%) 
 
The VASI reduction in vitiligo types of tacrolimus only group was noted as 
follows: - focal vitiligo 44.12%, segmental vitiligo 0%, and acral vitiligo 
0%. 
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VASI Reduction in Vitiligo Type in Tacrolimus with Steroids 
VASI 
reduction 
(at months) 
Acral Focal Segmental 
VASI 0m 0.4879 (100 %) 0.90938(100%) 0.05(100%) 
VASI 2m 0.48 (98.38%) 0.90813(99.865%) 0.025(50%) 
VASI 4m 0.39786(81.55%) 0.77063(84.74%) 0.025(50%) 
VASI 6m 0.35214(72.18%) 0.65775(72.33%) 0.005(10%) 
VASI 8m 0.35036(71.81%) 0.59213(65.11%) 0.005(10%) 
VASI 12m 0.34321(70.35%) 0.59213(65.11%) 0.005(10%) 
 
 
The VASI reduction in vitiligo types of tacrolimus with topical steroids 
group was as follows: segmental vitiligo 90%, focal vitiligo 34.89%, and 
acral vitiligo 29.65%. 
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Adverse Effects 
Effects Tacrolimus Tacrolimus with Steroids Total 
Atrophy 0 2 2 
Burning 5 0 5 
Total 5 2 7 
 
Side effects included mainly burning sensation in about 5 patients in 
tacrolimus only treated group where as in tacrolimus with steroid group it 
included atrophy in about 6 patientsts. 
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Total reduction in VASI: Physician’s Global assessment: 
 
 Tacrolimus 
Tacrolimus with 
steroids 
Score Comment  
No of 
pts 
% No of pts % 
5 No change 0% 10 41.67 7 30.45 
4 
Min 
improvement 
1-25% 3 12.5 2 8.69 
3 
Definite 
improvement 
26-50% 7 29.16 8 34.78 
2 
Marked 
improvement 
51-75% 1 4.16 2 8.69 
1 
Excellent 
improvement 
76-100% 3 12.5 4 17.39 
 
The mean physician’s global assessment score was 3.041 in Tacrolimus 
group and it was 3.261 in Tacrolimus with steroids group (P value 0.657). 
Physician’s global assessment clearly showed that only 29.16% of patients 
treated with Tacrolimus alone had definite improvement whereas 34.78% 
of patients treated by Tacrolimus with steroids had definite improvement. 
Physician’s global assessment clearly showed that only 12.5% of patients 
treated with Tacrolimus alone had excellent improvement whereas 17.39% 
of patients treated by Tacrolimus with steroids had excellent improvement. 
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Total reduction in VASI: Physician‘s Global Assessment. 
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Patient global assessment score 
 Tacrolimus Tacrolimus with steroids 
Score comment No of pts % No of pts % 
1 Much better 8 33.34% 8 34.78% 
2 Slightly better 6 25% 8 34.78% 
3 Same 10 41.67% 7 30.43% 
4 Worse 0 0% 0 0 
 
The mean patient global assessment score was 2.083 in Tacrolimus group 
and it was 1.957 in Tacrolimus with steroids group. 
Patient global assessment clearly showed that only 33.34% of patients 
treated with Tacrolimus alone had much better improvement whereas 
34.78% of patients treated by Tacrolimus with steroids had much better 
improvement. 
Patient global assessment clearly showed that 41.67%of patients treated 
with Tacrolimus alone had much better improvement whereas 30.43% of 
patients treated by Tacrolimus with steroids had no change. 
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GROUP-B 0.03% TACROLIMUS AND TOPICAL STEROIDS 
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DISCUSSION 
 
This clinical comparative trial explored the efficacy of 0.03% 
tacrolimus(T) alone in comparison with  0.03% tacrolimus with topical 
corticosteroids (mometaone furoate) (T+S)  in patients suffering from 
vitiligo less than 10% of body surface area involvement. 
The baseline demographic data and baseline characteristics in both study 
groups, when compared were similar. 
To our limited knowledge, there are no previous studies comparing the 
efficacy of 0.03% tacrolimus alone versus 0.03% tacrolimus and topical 
steroids. 
 The overall efficacy of 0.03% tacrolimus with topical corticosteroids 
(mometasone furoate) is slightly greater than 0.03% tacrolimus alone after 
the end of 12months with better response at 4 months in the former. This 
shows that 0.03% tacrolimus can be effectively used as topical 
monotherapy in patients with localized stable vitiligo. 
However patients in group of 0.03% tacrolimus with topical corticosteroids 
showed significant reduction in total body VASI score in 4 months when 
compared 0.03% tacrolimus alone. 
The reduction in former group is 16.92% when compared to 10.72% in 
latter group at 4 months of study period. This clearly shows that significant 
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repigmentation occurs earlier in patients treated with 0.03% tacrolimus 
with topical corticosteroids. 
 
Patients with focal vitiligo and segmental vitiligo showed better clinical 
response to 0.03% tacrolimus with topical corticosteroids. 
 
Patients with acral vitiligo did not respond to Tacrolimus or Tacrolimus 
and topical corticosteroids. 
 
Facial vitiligo responded better with tacrolimus alone. 
Genital vitiligo responded better to Tacrolimus and topical steroids as more 
female children were treated with combination than the male children. 
 
Vitiligo involving the upper limb and lower limbs showed better response 
with Tacrolimus and steroids and minimal response with Tacrolimus only. 
 
The secondary efficacy parameters like Physician’s Global Assessment 
show results in favour of Tacrolimus and topical steroids treated group. 
 
Apart from transient burning, no serious adverse effects were noted in T 
group. Atrophy was noted in Tacrolimus and topical steroids group. 
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There were hyperpigmented borders seen in patients treated with 
Tacrolimus and steroids which did not occur in patients treated with 
tacrolimus alone which showed homogenous pigmentation. 
 
During the follow up period of three months after completion of the study, 
none of the patients in both study groups showed clinical signs of relapse 
evidenced by the fact that VASI remains the same as that of 12 months. 
 
 Small sample size, lack of placebo control and shorter duration of study 
were the major pitfalls in this study. 
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CONCLUSION 
 
 0.03 % Tacrolimus alone can be effectively used as topical 
monotherapy   for treating localized stable Vitiligo.  
 Facial vitiligo responds well to 0.03% tacrolimus alone and no need 
to add steroids topically as it increases the risk of atrophy. 
 When midpotent topical corticosteroids are combined with 
tacrolimus there was significant reduction in VASI score at an earlier 
date, when compared to tacrolimus alone. 
  The overall efficacy of tacrolimus with steroids is 32.55%, which 
was only slightly higher than tacrolimus only 31.47%. 
 Acral vitiligo does not respond to tacrolimus alone or tacrolimus 
with topical corticosteroids.  
  When midpotent topical corticosteroids are combined with 
tacrolimus was most effective in focal and segmental vitiligo. 
 Vitiligo involving the upper limb and lower limbs showed better 
response with T+S. 
 Tacrolimus alone was safe as there were no serious systemic or         
cutaneous adverse effects apart from transient burning in a few 
patients unlike steroids which caused atrophy in few patients.    
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PROFORMA 
Name                                                                               Case no 
Age                                                                                  Hospital no 
Sex                                                                                   Date of enrolment 
Address 
Occupation                                                                                                                                                                                                                                             
HISTORY: 
Presenting complaints: No of patches, sites 
Duration: 
Activity: 
Factors exacerbating  –seasonal, infection, emotional, drugs, sunlight. 
History of itching – 
Hisory of drug intake prior to the onset of lesions. 
History of injury – physical – present/absent. 
                                 Chemical – present/absent. 
History of photosensitivity – 
History of GIT disturbances - 
Family history – Consanguinity in parents 
                              Other  family members with vitiligo 
                               Associated diseases in family. 
 
Associated autoimmune disease – hypothyroidism                                    
pernicious anemia 
Rheumatoid arthritis                       
addisons disease 
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 Hyperthyroidism                          
 Diabetes mellitus 
  Alopecia areata                                
  Atopic dermatitis 
Past history – Diabetes mellitus/ hypertension/ asthma/epilepsy/ 
tuberculosis. 
Personal history – Diet/ apetite/ sleep/ bladder and bowel habits. 
Examination 
Sites – sunexposed/ covered areas. 
Face, neck/ trunk/ genital/extremities. 
Total Body surface involvement in percentage - 
Leukotrichia – present/absent. 
Koebners phenomenon – present/absent. 
Type of vitiligo – focal / mucosal/acral/segmental. 
Associated skin disease if any 
Associated systemic disorder if any. 
General Examination 
1. Built 
2. Height 
3. Weight 
4. Pallor 
5. Icterus 
6. Cyanosis 
7. Clubbing 
8. Lymphadenopathy 
9. Edema 
10. Vital – pulse, BP, RR 
11. Systemic  examination – CVS, RS, P/A, CNS. 
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INVESTIGATIONS 
Hb 
TC 
DC 
ESR 
Peripheral smear 
Blood group 
Blood sugar 
Blood urea 
Serum creatinine 
Liver Function Test 
Thyroid Function Test 
 
GROUP A – 0.03% TACROLIMUS ONLY. 
 
 
 
 14w 16w 18w 20w 22w 24w 
Size of the patch       
No of patches       
Erythema       
Perifollicular repigmentation       
Pigmentation over margins       
Hair pigmentation       
 
 
 
 
 0w 2w 4w 6w 8w 10w 12w 
Size of the patch        
No of patches        
Erythema        
Perifollicular repigmentation        
Pigmentation over margins        
Hair pigmentation        
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GROUP – B 0.03% TACROLIMUS AND TOPICAL STEROIDS. 
 26w 28w 30w 32w 34w 36w 38w 
Size of the patch        
No of patches        
Erythema        
Perifollicular repigmentation        
Pigmentation over margins        
Hair pigmentation        
 
 40w 42w 44w 46w 48w   
Size of the patch        
No of patches        
Erythema        
Perifollicular repigmentation        
Pigmentation over margins        
Hair pigmentation        
 
Physician global assessment  
 0w 2w 4w 6w 8w 10w 12w 
grade        
 
 14w 16w 18w 20w 22w 24w 
grade       
 
 26w 28w 30w 32w 34w 36w 
grade       
 
 38w 40w 42w 44w 46w 48w 
grade       
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Physician Global Assessment  
Grade Improvement in % Comments 
1 76%-100% Excellent improvement 
2 51%-75% Marked improvement 
3 26%-50% Definite improvement 
4 1% -25% Minimal improvement 
5 0% No change 
 
Patient global assessment score 
 0w 2w 4w 6w 8w 10w 12w 
Grade        
 
 14w 16w 18w 20w 22w 24w 
Grade       
 
 26w 28w 30w 32w 34w 36w 
Grade       
 
 38w 40w 42w 44w 46w 48w 
Grade       
 
Grade 
1                       Much better 
2                       Slightly better 
3                       Same 
4                       Worse 
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Adverse events 
Adverse 
Event 
Severity Onset Course Action Relationship 
to 
study drug 
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KEY TO MASTER CHART 
 
VASI –Vitiligo Area Scoring Index. 
Phy G A - Physician Global Assessment score. 
Pat G A – Patient Global Assessment score. 
 
 
 
 
 
 
 
 
 
 
 
 
Group A: 0.03% Tacrolimus only. 
Sl 
No 
Name Age Sex 
Duration 
of disease 
Area 
involved 
Type of 
vitiligo 
VASI 
0m 
VASI 
2m 
VASI 
4m 
VASI 
6m 
VASI 
8m 
VASI 
12m 
Phy 
G A 
Pat 
G A 
Side 
effects 
1 NANDA 5yrs MALE 2yrs GENITALIA FOCAL 0.2 0.2 0.2 0.15 0.15 0.15 4 2 BURNING 
2 NITHYA 13yrs FEMALE 6months TRUNK FOCAL 0.05 0.025 0.025 0.005 0.005 0.005 1 2 - 
3 RANJITH 12yrs MALE 3yrs FACE FOCAL 0.1 0.09 0.09 0.075 0.05 0 1 2 - 
4 DIVYA 8yrs FEMALE 1yr GENITALIA FOCAL 0.375 0.375 0.375 0.375 0.225 0.225 3 2 BURNING 
5 SATISH 14yrs MALE 3yrs TRUNK SEGMENTAL 0.375 0.375 0.375 0.375 0.375 0.375 5 3 - 
6 ELAIRASAN 9yrs MALE 1yr HAND ACRAL 0.1 0.1 0.1 0.1 0.1 0.1 5 3 BURNING 
7 SELVAM 8yrs MALE 2yrs GENITALIA FOCAL 0.1 0.1 0.1 0.1 0.1 0.1 5 3 - 
8 SAKTHI 11yrs FEMALE 6months GENITALIA FOCAL 0.25 0.25 0.125 0.125 0.125 0.025 1 2 - 
9 MADHU 10yrs FEMALE 2yrs TRUNK FOCAL 0.375 0.375 0.375 0.375 0.375 0.375 5 3 - 
10 VIDYA 7yrs FEMALE 4yrs TRUNK FOCAL 0.375 0.375 0.375 0.375 0.225 0.225 3 2 - 
11 SATYA 9yrs FEMALE 3yrs TRUNK FOCAL 0.375 0.375 0.375 0.375 0.375 0.375 5 3 - 
12 BALAN 11yrs MALE 2yrs FEET ACRAL 0.1 0.1 0.1 0.1 0.1 0.1 5 3 BURNING 
13 PRIYA 12yrs FEMALE 1yr FACE FOCAL 0.05 0.025 0.025 0.005 0.005 0.005 1 1 - 
14 GOPI 8yrs MALE 4yrs LOWERLIMB FOCAL 0.375 0.375 0.375 0.375 0.375 0.375 5 3 - 
15 NAGESH 5yrs MALE 1yr TRUNK FOCAL 0.05 0.025 0.025 0.005 0.005 0.005 1 1 - 
16 LATHA 6yrs FEMALE 3yrs GENITALIA FOCAL 0.25 0.25 0.125 0.125 0.125 0.025 1 1 - 
17 HEMALATHA 8yrs FEMALE 4yrs UPPERLIMB FOCAL 0.06 0.06 0.06 0.06 0.06 0.06 5 3 - 
18 RANJITHA 13yrs FEMALE 3yrs TRUNK FOCAL 0.05 0.05 0.05 0.025 0.025 0.025 1 1 - 
19 JAYAKUMAR 6yrs MALE 2yrs HAND ACRAL 0.5 0.5 0.5 0.5 0.5 0.5 5 3 - 
20 MAMTHA 7yrs FEMALE 4yrs GENITALIA FOCAL 0.25 0.25 0.25 0.125 0.125 0.125 3 1 BURNING 
21 MAHESH 11yrs MALE 3yrs FACE FOCAL 0.05 0.025 0.025 0.005 0.005 0.005 1 1 - 
22 RAJA 12yrs MALE 4yrs FACE FOCAL 0.25 0.25 0.125 0.125 0.125 0.025 1 1 - 
23 MURUGAN 8yrs MALE 2yrs FEET ACRAL 0.06 0.06 0.06 0.06 0.06 0.06 5 3 - 
24 RANI 9yrs FEMALE 3yrs FACE FOCAL 0.05 0.025 0.025 0.005 0.005 0.005 1 1 - 
25 ANAND  Dropout             
 
Group B: 0.03% Tacrolimus and topical corticosteroids. 
Sl 
No 
Name Age Sex 
Duration 
of disease 
Area 
involved 
Type of 
vitiligo 
VASI 
0m 
VASI 
2m 
VASI 
4m 
VASI 
6m 
VASI 
8m 
VASI 
12m 
Phy 
G A 
Pat 
G A 
Side 
effects 
1 JAGAN 8yrs MALE 2yrs FACE FOCAL 0.225 0.225 0.225 0.187 0.187 0.187 4 2 ATROPY 
2 MANI 8yrs MALE 3yrs UPPERLIMB FOCAL 0.75 0.75 0.5 0.5 0.5 0.5 3 1 - 
3 PAVITHRA 10yrs FEMALE 4yrs FACE SEGMENTAL 0.05 0.025 0.025 0.005 0.005 0.005 1 2 ATROPY 
4 RAJ 13yrs MALE 5yrs UPPERLIMB FOCAL 1 0.9 0.75 0.5 0.5 0.5 3 1 - 
5 RAKESH 10yrs MALE 2yrs UPPERLIMB FOCAL 1.5 1.5 1 1 1 1 3 1 - 
6 LAKSHMI 7yrs FEMALE 1yr TRUNK FOCAL 3.6 3.6 3 3 3 3 4 2 - 
7 SARANYA 6yrs FEMALE 2yrs LOWERLIMB FOCAL 0.25 0.25 0.25 0.1 0.1 0 1 1 - 
8 ANIL 10yrs MALE 3yrs FEET ACRAL 0.06 0.06 0.06 0.06 0.06 0.06 5 3 - 
9 BALAJI 5yrs MALE 4yrs FEET ACRAL 0.375 0.375 0.375 0.375 0.375 0.375 5 3 - 
10 ASHWIN 11yrs MALE 1yr HAND ACRAL 1.35 1.35 1.35 1.35 1.35 1.35 5 3 - 
11 HARISH 12yrs MALE 4yrs LOWERLIMB FOCAL 0.375 0.375 0.375 0.25 0.25 0.25 3 2 - 
12 PAVITHRA 10yrs FEMALE 3yrs FEET ACRAL 0.06 0.06 0.06 0.06 0.06 0.06 5 3 - 
13 KAVIBHARATHI 7yrs FEMALE 2yrs LOWERLIMB FOCAL 0.1 0.1 0.1 0 0 0 1 1 - 
14 SUMATHI 7yrs FEMALE 2yrs TRUNK FOCAL 0.75 0.75 0.75 0.5 0.5 0.5 3 2 - 
15 JAYAKUMAR 10yrs MALE 3yrs TRUNK FOCAL 0.5 0.5 0.5 0.5 0.5 0.5 5 3 - 
16 ASHA 10yrs FEMALE 2yrs FACE FOCAL 1 1 0.75 0.5 0.25 0.25 2 1 - 
17 PINKY 10yrs FEMALE 2yrs TRUNK FOCAL 1 1 0.75 0.5 0.25 0.25 2 1 - 
18 BHARATHI 8yrs FEMALE 1yr GENITALIA FOCAL 0.1 0.1 0.1 0 0 0 1 1 - 
19 AKSHAYA 10yrs FEMALE 3yrs GENITALIA FOCAL 0.1 0.09 0.09 0.075 0.05 0.05 3 2 - 
20 PADMAPRIYA 8yrs FEMALE 1yr UPPERLIMB FOCAL 0.1 0.09 0.09 0.075 0.05 0.05 3 2 - 
21 BHARATH 10yrs MALE 2.6yrs LOWERLIMB FOCAL 0.75 0.75 0.5 0.5 0.5 0.5 3 2 - 
22 SHAKTHIVEL 9yrs MALE 3yrs FEET ACRAL 0.1 0.1 0.1 0.1 0.1 0.1 5 3 - 
23 MURUGAN 7yrs MALE 6months HAND ACRAL 0.06 0.06 0.06 0.06 0.06 0.06 5 3 - 
24 SARANYA   Dropout            
25 RAMKUMAR   Dropout            
 
